Medical/Pharmacy Policy Updates Effective 12/15/2026
Summary
Blue Cross and Blue Shield of Nebraska (BCBSNE) is implementing a new medical policy (MPC X.242 OptimizeRX) effective 12/15/2026 that establishes step therapy requirements for multiple biologic medications. Preauthorization is now required for all nonpreferred products, and patients must demonstrate contraindication, intolerance, or failure to a preferred product before nonpreferred alternatives will be considered. This applies to both new and established patients across denosumab, infliximab, rituximab, tocilizumab, and trastuzumab drug classes.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of Nebraska and other payers every day and email you when a change matches your specialty and state.